Published in J Biol Chem on August 05, 2008
Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res (2010) 1.59
miR-150 regulates the development of NK and iNKT cells. J Exp Med (2011) 1.53
miR-186 is decreased in aged brain and suppresses BACE1 expression. J Neurochem (2016) 1.49
Identification of Differentially Expressed MicroRNAs in Osteosarcoma. Sarcoma (2011) 1.48
MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells. Carcinogenesis (2011) 1.39
Purinergic signalling and cancer. Purinergic Signal (2013) 1.18
miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One (2013) 1.18
Identification of ovarian cancer metastatic miRNAs. PLoS One (2013) 1.09
MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death. Cardiovasc Res (2015) 0.99
miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC. PLoS One (2014) 0.98
An analysis of the global expression of microRNAs in an experimental model of physiological left ventricular hypertrophy. PLoS One (2014) 0.97
Residues 155 and 348 contribute to the determination of P2X7 receptor function via distinct mechanisms revealed by single-nucleotide polymorphisms. J Biol Chem (2011) 0.95
MicroRNA 802 stimulates ROMK channels by suppressing caveolin-1. J Am Soc Nephrol (2011) 0.95
Minireview: The roles of small RNA pathways in reproductive medicine. Mol Endocrinol (2011) 0.92
CXCL13 drives spinal astrocyte activation and neuropathic pain via CXCR5. J Clin Invest (2016) 0.92
Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes. Front Mol Neurosci (2011) 0.90
miR-186 inhibits muscle cell differentiation through myogenin regulation. J Biol Chem (2014) 0.90
Regulation of lung surfactant secretion by microRNA-150. Biochem Biophys Res Commun (2012) 0.88
Signaling through purinergic receptors for ATP induces human cutaneous innate and adaptive Th17 responses: implications in the pathogenesis of psoriasis. J Immunol (2013) 0.86
miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro. Med Sci Monit (2014) 0.85
microRNA-150 promotes cervical cancer cell growth and survival by targeting FOXO4. BMC Mol Biol (2015) 0.84
Activation of P2X(7)-mediated apoptosis Inhibits DMBA/TPA-induced formation of skin papillomas and cancer in mice. BMC Cancer (2009) 0.84
Global microRNA expression profiling: curcumin (diferuloylmethane) alters oxidative stress-responsive microRNAs in human ARPE-19 cells. Mol Vis (2013) 0.83
Role of microRNA-150 in solid tumors. Oncol Lett (2015) 0.82
Regulation of P2X(7) gene transcription. Purinergic Signal (2009) 0.82
A statistically inferred microRNA network identifies breast cancer target miR-940 as an actin cytoskeleton regulator. Sci Rep (2015) 0.82
P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin. Purinergic Signal (2009) 0.81
MicroRNA-186 targets Yes-associated protein 1 to inhibit Hippo signaling and tumorigenesis in hepatocellular carcinoma. Oncol Lett (2016) 0.81
microRNA targeting of the P2X7 purinoceptor opposes a contralateral epileptogenic focus in the hippocampus. Sci Rep (2015) 0.79
Signalling molecules in the urothelium. Biomed Res Int (2014) 0.79
Purinergic signalling in the reproductive system in health and disease. Purinergic Signal (2013) 0.78
The effects of lidocaine and procaine on microRNA expression of adipocyte-derived adult stem cells. Korean J Anesthesiol (2012) 0.77
miR-203 enhances let-7 biogenesis by targeting LIN28B to suppress tumor growth in lung cancer. Sci Rep (2017) 0.75
Synovium-Derived MicroRNAs Regulate Bone Pathways in Rheumatoid Arthritis. J Bone Miner Res (2016) 0.75
Interleukin-6 and microRNA profiles induced by oral bacteria in human atheroma derived and healthy smooth muscle cells. Springerplus (2015) 0.75
P2X7 mRNA expression in non-small cell lung cancer: MicroRNA regulation and prognostic value. Oncol Lett (2014) 0.75
Genetic polymorphisms in miRNAs targeting the estrogen receptor and their effect on breast cancer risk. Meta Gene (2014) 0.75
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The functions of animal microRNAs. Nature (2004) 64.85
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell (2007) 38.42
Systematic discovery of regulatory motifs in human promoters and 3' UTRs by comparison of several mammals. Nature (2005) 31.60
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Principles of microRNA-target recognition. PLoS Biol (2005) 23.70
The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science (2005) 20.51
The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol (1999) 17.82
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell (2005) 15.26
Receptors for purines and pyrimidines. Pharmacol Rev (1998) 13.92
Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res (2005) 9.80
MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell (2007) 9.33
MicroRNA-cancer connection: the beginning of a new tale. Cancer Res (2006) 7.38
The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science (1996) 7.10
Determinants of targeting by endogenous and exogenous microRNAs and siRNAs. RNA (2007) 6.44
Signal transduction via P2-purinergic receptors for extracellular ATP and other nucleotides. Am J Physiol (1993) 5.64
miRNA profiling of naïve, effector and memory CD8 T cells. PLoS One (2007) 5.43
Regulation of mRNA stability in mammalian cells. Gene (2001) 4.55
miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A (2007) 4.15
Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood (2007) 3.64
Patterns of known and novel small RNAs in human cervical cancer. Cancer Res (2007) 3.46
International union of pharmacology. XXIV. Current status of the nomenclature and properties of P2X receptors and their subunits. Pharmacol Rev (2001) 3.26
Predicting and validating microRNA targets. Genome Biol (2004) 2.54
Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. J Physiol (1999) 2.37
Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene (2007) 2.36
Regulated expression of microRNAs in normal and polycythemia vera erythropoiesis. Exp Hematol (2007) 1.98
Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res (2007) 1.83
MicroRNA: past and present. Front Biosci (2007) 1.79
P2X receptor trafficking in neurons is subunit specific. J Neurosci (2002) 1.60
P2X receptors: an emerging channel family. Eur J Neurosci (1996) 1.53
Expression of P2X(7) purinoceptors on human lymphocytes and monocytes: evidence for nonfunctional P2X(7) receptors. Am J Physiol Cell Physiol (2000) 1.40
P2X7 receptor-mediated apoptosis of human cervical epithelial cells. Am J Physiol Cell Physiol (2004) 1.35
The DNA damage response, immunity and cancer. Semin Cancer Biol (2006) 1.34
Pharmacological characterization of ATP- and LPS-induced IL-1beta release in human monocytes. Br J Pharmacol (1999) 1.34
Hypertonic stress increases T cell interleukin-2 expression through a mechanism that involves ATP release, P2 receptor, and p38 MAPK activation. J Biol Chem (2002) 1.30
A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem (2006) 1.30
ATP released by LPS increases nitric oxide production in raw 264.7 macrophage cell line via P2Z/P2X7 receptors. Neurochem Int (1998) 1.24
Gene structure and chromosomal localization of the human P2X7 receptor. Receptors Channels (1998) 1.19
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Exp Hematol (2007) 1.14
Role of alterations in the apoptotic machinery in sensitivity of cancer cells to treatment. Curr Pharm Des (2006) 1.12
Mitochondrial DNA mutations and apoptosis in mammalian aging. Cancer Res (2006) 1.10
Cloned ligand-gated channels activated by extracellular ATP (P2X receptors). J Membr Biol (1997) 1.10
Human uterine cervical epithelial cells grown on permeable support--a new model for the study of differentiation. Differentiation (1994) 1.10
ATP stimulates GRK-3 phosphorylation and beta-arrestin-2-dependent internalization of P2X7 receptor. Am J Physiol Cell Physiol (2005) 1.08
Purinergic receptor regulation of LPS-induced signaling and pathophysiology. J Endotoxin Res (2003) 1.04
Antiapoptotic effects of estrogen in normal and cancer human cervical epithelial cells. Endocrinology (2004) 1.03
Epidermal growth factor facilitates epinephrine inhibition of P2X7-receptor-mediated pore formation and apoptosis: a novel signaling network. Endocrinology (2004) 0.95
Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol Oncol (2007) 0.93
Effect of ATP on intracellular pH in pancreatic ducts involves P2X7 receptors. Cell Physiol Biochem (2003) 0.92
The distribution of P2X receptor clusters on individual neurons in sympathetic ganglia and their redistribution on agonist activation. J Biol Chem (2000) 0.90
Rescue of a mitochondrial deficiency causing Leber Hereditary Optic Neuropathy. Ann Neurol (2002) 2.13
FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development (2010) 1.86
Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob Agents Chemother (2006) 1.79
Osteosarcoma. J Am Acad Orthop Surg (2009) 1.73
Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res (2005) 1.66
Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst (2009) 1.59
Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecol Oncol (2009) 1.45
Susceptibility of treatment-naive hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors. Antimicrob Agents Chemother (2010) 1.42
Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer. Neoplasia (2011) 1.39
P2X7 receptor-mediated apoptosis of human cervical epithelial cells. Am J Physiol Cell Physiol (2004) 1.35
A truncated P2X7 receptor variant (P2X7-j) endogenously expressed in cervical cancer cells antagonizes the full-length P2X7 receptor through hetero-oligomerization. J Biol Chem (2006) 1.30
Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol Med (2013) 1.26
Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir Ther (2005) 1.25
HER2/ErbB2-induced breast cancer cell migration and invasion require p120 catenin activation of Rac1 and Cdc42. J Biol Chem (2010) 1.24
Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2011) 1.23
Regulation of fosB and DeltafosB mRNA expression: in vivo and in vitro studies. Brain Res (2007) 1.19
Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. Parkinsonism Relat Disord (2008) 1.16
Efficiency and safety of AAV-mediated gene delivery of the human ND4 complex I subunit in the mouse visual system. Invest Ophthalmol Vis Sci (2009) 1.14
Dysregulated autophagy in the RPE is associated with increased susceptibility to oxidative stress and AMD. Autophagy (2014) 1.11
ATP stimulates GRK-3 phosphorylation and beta-arrestin-2-dependent internalization of P2X7 receptor. Am J Physiol Cell Physiol (2005) 1.08
Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction. Proc Natl Acad Sci U S A (2013) 1.07
β-Secretase (BACE1) inhibition causes retinal pathology by vascular dysregulation and accumulation of age pigment. EMBO Mol Med (2012) 1.05
PEDF regulates vascular permeability by a γ-secretase-mediated pathway. PLoS One (2011) 1.05
Autophagy in the retina: a potential role in age-related macular degeneration. Adv Exp Med Biol (2012) 1.02
Gynecologic cytology on conventional and liquid-based preparations: a comprehensive review of similarities and differences. Diagn Cytopathol (2012) 1.00
Specific splice variants are associated with Parkinson's disease. Mov Disord (2013) 1.00
Placenta growth factor-1 exerts time-dependent stabilization of adherens junctions following VEGF-induced vascular permeability. PLoS One (2011) 1.00
Free insulin-like growth factor binding protein-3 (IGFBP-3) reduces retinal vascular permeability in association with a reduction of acid sphingomyelinase (ASMase). Invest Ophthalmol Vis Sci (2011) 1.00
Calcium-sensing receptor decreases cell surface expression of the inwardly rectifying K+ channel Kir4.1. J Biol Chem (2010) 0.99
The 5HT1a receptor agonist 8-Oh DPAT induces protection from lipofuscin accumulation and oxidative stress in the retinal pigment epithelium. PLoS One (2012) 0.99
Tumoral calcinosis in the cervical spine in a patient with CREST syndrome. A case report. J Bone Joint Surg Am (2006) 0.98
γ-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1. J Biol Chem (2011) 0.98
Estrogen abrogates transcervical tight junctional resistance by acceleration of occludin modulation. J Clin Endocrinol Metab (2004) 0.97
Fine needle aspiration cytology of breast cylindroma in a woman with familial cylindromatosis: a case report. Acta Cytol (2004) 0.97
Changes in tight junctional resistance of the cervical epithelium are associated with modulation of content and phosphorylation of occludin 65-kilodalton and 50-kilodalton forms. Endocrinology (2005) 0.97
The promise of neuroprotective agents in Parkinson's disease. Front Neurol (2011) 0.96
Epidermal growth factor facilitates epinephrine inhibition of P2X7-receptor-mediated pore formation and apoptosis: a novel signaling network. Endocrinology (2004) 0.95
The P2X7 receptor: a novel biomarker of uterine epithelial cancers. Cancer Epidemiol Biomarkers Prev (2006) 0.95
Per2 mutation recapitulates the vascular phenotype of diabetes in the retina and bone marrow. Diabetes (2012) 0.95
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res (2007) 0.94
Aryl hydrocarbon receptor deficiency causes dysregulated cellular matrix metabolism and age-related macular degeneration-like pathology. Proc Natl Acad Sci U S A (2013) 0.94
Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol Oncol (2007) 0.93
Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside/nucleotide analogues. Antivir Chem Chemother (2009) 0.92
Histidine-proline rich glycoprotein (HPRG) binds and transduces anti-angiogenic signals through cell surface tropomyosin on endothelial cells. Thromb Haemost (2004) 0.91
Histologic follow-up of atypical endocervical cells. Liquid-based, thin-layer preparation vs. conventional Pap smear. Acta Cytol (2002) 0.91
Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers. Int J Gynecol Cancer (2012) 0.91
Estrogen regulates epithelial cell deformability by modulation of cortical actomyosin through phosphorylation of nonmuscle myosin heavy-chain II-B filaments. Endocrinology (2006) 0.90
The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci U S A (2002) 0.90
Ovarian hyperstimulation by LH leads to mammary gland hyperplasia and cancer predisposition in transgenic mice. Endocrinology (2002) 0.90
Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. Int J Gynecol Cancer (2013) 0.89
Pharmacological characterization of a novel nonpeptide antagonist radioligand, (+/-)-N-[2-methyl-4-methoxyphenyl]-1-(1-(methoxymethyl) propyl)-6-methyl-1H-1,2,3-triazolo[4,5-c]pyridin-4-amine ([3H]SN003) for corticotropin-releasing factor1 receptors. J Pharmacol Exp Ther (2003) 0.89
MUC1 is expressed at high frequency in early-stage basal-like triple-negative breast cancer. Hum Pathol (2013) 0.88
18F-fluoro-2-deoxy-D-glucose positron emission tomography standard uptake value ratio as an indicator of cervical cancer chemoradiation therapeutic response. Int J Gynecol Cancer (2011) 0.87
Low-dose-rate brachytherapy for treatment of uterine didelphys malignancy. J Clin Oncol (2010) 0.87
Ribonucleotide reductase inhibition restores platinum-sensitivity in platinum-resistant ovarian cancer: a Gynecologic Oncology Group Study. J Transl Med (2012) 0.87
Regulation of retention of FosB intron 4 by PTB. PLoS One (2007) 0.86
Radiation therapy in addition to gross total resection of retroperitoneal sarcoma results in prolonged survival: results from a single institutional study. J Oncol (2009) 0.86
Targeting the IRE1α/XBP1 and ATF6 arms of the unfolded protein response enhances VEGF blockade to prevent retinal and choroidal neovascularization. Am J Pathol (2013) 0.85
Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5. Curr Cancer Drug Targets (2005) 0.84
Retroperitoneal liposarcoma. J Urol (2007) 0.84
Posttherapy residual disease associates with long-term survival after chemoradiation for bulky stage 1B cervical carcinoma: a Gynecologic Oncology Group study. Am J Obstet Gynecol (2010) 0.84
Activation of P2X(7)-mediated apoptosis Inhibits DMBA/TPA-induced formation of skin papillomas and cancer in mice. BMC Cancer (2009) 0.84
Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions. Int J Gynecol Pathol (2007) 0.84
A network approach to diagnostic biomarkers in progressive supranuclear palsy. Mov Disord (2013) 0.83
Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells. J Pathol (2010) 0.83
Dicer expression exhibits a tissue-specific diurnal pattern that is lost during aging and in diabetes. PLoS One (2013) 0.83
Molecular evidence for independent origin of multifocal neuroendocrine tumors of the enteropancreatic axis. Cancer Res (2006) 0.82
Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. Breast Cancer Res Treat (2014) 0.82
Regulation of P2X(7) gene transcription. Purinergic Signal (2009) 0.82
Indeterminate and erroneous fine-needle aspirates of breast with focus on the 'true gray zone': a review. Acta Cytol (2013) 0.81
Testicular vasculitis. J Urol (2006) 0.81
ASPL-TFE3 translocation in vulvovaginal alveolar soft part sarcoma. Int J Gynecol Pathol (2014) 0.81
Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Can J Physiol Pharmacol (2002) 0.81
P2X(7) receptor expression is decreased in epithelial cancer cells of ectodermal, uro-genital sinus, and distal paramesonephric duct origin. Purinergic Signal (2009) 0.81
Progressive osteolysis and surface chondrolysis of the proximal humerus following influenza vaccination. Orthopedics (2012) 0.80
[Multiple endocrine neoplasia type 2A caused by a p.C618R RET proto-oncogene mutation in a Chinese pedigree]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi (2014) 0.79
FOXC1 is enriched in the mammary luminal progenitor population, but is not necessary for mouse mammary ductal morphogenesis. Biol Reprod (2013) 0.79
Evidence for transformation of fibroadenoma of the breast to malignant phyllodes tumor. Appl Immunohistochem Mol Morphol (2009) 0.79
Dynamics of MRI-Guided thermal ablation of VX2 tumor in paraspinal muscle of rabbits. IEEE Trans Biomed Eng (2008) 0.78
Chimeric glutathione S-transferases containing inserts of kininogen peptides: potential novel protein therapeutics. J Biol Chem (2012) 0.78
Magnetic resonance imaging and model prediction for thermal ablation of tissue. J Magn Reson Imaging (2007) 0.78
Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother (2013) 0.77
Analysis of microsatellite instability and X-inactivation in ovarian borderline tumors lacking numerical abnormalities by comparative genomic hybridization. Cancer Genet Cytogenet (2003) 0.77
MR monitoring of NaCl-enhanced radiofrequency ablations: observations on low- and high-field-strength MR images with pathologic correlation. Radiology (2010) 0.77
Abrupt loss of MLH1 and PMS2 expression in endometrial carcinoma: molecular and morphologic analysis of 6 cases. Am J Surg Pathol (2015) 0.77
Molecular genetic evidence supporting the neoplastic nature of the Leydig cell component of ovarian Sertoli-Leydig cell tumors. Int J Gynecol Pathol (2007) 0.76
Papanicolaou tests with coexisting squamous and glandular abnormalities. Cancer Cytopathol (2014) 0.76
Is progesterone a vasodilator? Menopause (2004) 0.75
Effects of estrogen on vaginal innervation: denervation or remodeling? Menopause (2012) 0.75
Histopathologic correlation of atypical parakeratosis diagnosed on cervicovaginal cytology. Acta Cytol (2003) 0.75
Significance of histiocytes on otherwise-normal cervical smears from postmenopausal women. A retrospective study of 108 cases. Acta Cytol (2003) 0.75
[Changes of semen quality in uremia patients]. Zhonghua Nan Ke Xue (2004) 0.75